CN106860852A - 一种用于结合治疗胃病的粘液西药 - Google Patents
一种用于结合治疗胃病的粘液西药 Download PDFInfo
- Publication number
- CN106860852A CN106860852A CN201710086313.7A CN201710086313A CN106860852A CN 106860852 A CN106860852 A CN 106860852A CN 201710086313 A CN201710086313 A CN 201710086313A CN 106860852 A CN106860852 A CN 106860852A
- Authority
- CN
- China
- Prior art keywords
- mucus
- western medicine
- combined treatment
- stomach trouble
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002784 stomach Anatomy 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 210000003097 mucus Anatomy 0.000 title claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 23
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract description 17
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims abstract description 17
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims abstract description 16
- -1 methoxy propoxy Chemical group 0.000 claims abstract description 16
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 16
- 102000009338 Gastric Mucins Human genes 0.000 claims abstract description 15
- 108010009066 Gastric Mucins Proteins 0.000 claims abstract description 15
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 claims abstract description 15
- BGYPHYAFWDUNDD-UHFFFAOYSA-N 1h-benzimidazole;sodium Chemical compound [Na].C1=CC=C2NC=NC2=C1 BGYPHYAFWDUNDD-UHFFFAOYSA-N 0.000 claims abstract description 14
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960000381 omeprazole Drugs 0.000 claims abstract description 13
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960004503 metoclopramide Drugs 0.000 claims abstract description 11
- 238000009835 boiling Methods 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229940096382 omeprazole 40 mg Drugs 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 229940024545 aluminum hydroxide Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- IAKOZHOLGAGEJT-UHFFFAOYSA-N 1,1,1-trichloro-2,2-bis(p-methoxyphenyl)-Ethane Chemical compound C1=CC(OC)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(OC)C=C1 IAKOZHOLGAGEJT-UHFFFAOYSA-N 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 241000165940 Houjia Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000012895 Gastric disease Diseases 0.000 abstract description 2
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000006641 stabilisation Effects 0.000 abstract description 2
- 238000011105 stabilization Methods 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 208000001762 Gastric Dilatation Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种用于结合治疗胃病的粘液西药，它由以下原料混合加工而成，各原料的重量配比如下：甲氧氯普胺片40～85mg、奥美拉唑30～50mg、氢氧化铝20～60mg、维生素B28～30mg、胃膜素15～40mg、磷酸铝10～25mg、甲氧基丙氧基5～15mg、苯并咪唑钠盐25～60mg；本发明疗效稳定、标本兼治，服用方便、简单，无异味且无毒性副作用，安全可靠，制造工艺简单，生产成本低，具有消炎、止痛功效，适合胃病患者使用。
Description
技术领域
本发明涉及的是胃病药物技术领域，具体的说是一种用于结合治疗胃病的粘液西药。
背景技术
所谓胃病，是与胃相关的许多疾病的统称。它们有相似的症状，如上腹部不适、疼痛、暖气、返酸等。临床上常见的胃病有：急性胃炎、慢性胃炎、功能性消化不良、胃潴留、胃溃疡、急性胃扩张、胃息肉和胃癌等等。
在当今这个快速发展的时代里，人们的生活水平以及物质生活在不断的提高，但是为了适应这个快速发展的时代，人们的生活习惯以及饮食规律却变得不是很规律，在出差或者工作很忙碌的时候，常常会出现饿一顿饱一顿的现象，或者为了照顾生意经常陪客户大吃大喝，酗酒，抽烟，严重影响了饮食，增添了胃的负担，往往会因此而造成胃部疾病，影响人类的身体健康。
现有的胃病中西药的药物种类很多，但是普便存在使用效果不佳，中药的服用很麻烦，往往需要煎煮之后才可以服用，而且中药的味道很刺鼻，会严重影响患者的服用心情，对药物有一种抵抗心理，从而影响治疗效果；现有的西药大多数是是胶囊，有的胶囊还比较大，患者在服用的时候往往会出现难以吞下去的现象，使用麻烦。
发明内容
本发明的目的在于针对现有技术的缺陷和不足，提供了一种用于结合治疗胃病的粘液西药。
为实现上述目的，本发明采用的技术方案是：
一种用于结合治疗胃病的粘液西药，它由以下原料混合加工而成，各原料的重量配比如下：甲氧氯普胺片40～85mg、奥美拉唑30～50mg、氢氧化铝20～60mg、维生素B2 8～30mg、胃膜素15～40mg、磷酸铝10～25mg、甲氧基丙氧基5～15mg、苯并咪唑钠盐25～60mg。
进一步，所述一种用于结合治疗胃病的粘液西药，它由以下原料混合加工而成，各原料的重量配比如下：甲氧氯普胺片40mg、奥美拉唑30mg、氢氧化铝20mg、维生素B2 8mg、胃膜素15mg、磷酸铝10mg、甲氧基丙氧基5mg、苯并咪唑钠盐25mg。
进一步，所述一种用于结合治疗胃病的粘液西药，它由以下原料混合加工而成，各原料的重量配比如下：甲氧氯普胺片85mg、奥美拉唑50mg、氢氧化铝60mg、维生素B230mg、胃膜素40mg、磷酸铝25mg、甲氧基丙氧基15mg、苯并咪唑钠盐60mg。
进一步，所述一种用于结合治疗胃病的粘液西药，它由以下原料混合加工而成，各原料的重量配比如下：甲氧氯普胺片60mg、奥美拉唑40mg、氢氧化铝45mg、维生素B2 15mg、胃膜素20mg、磷酸铝18mg、甲氧基丙氧基12mg、苯并咪唑钠盐35mg。
进一步，所述一种用于结合治疗胃病的粘液西药，其制备方法是：将甲氧氯普胺片、奥美拉唑、氢氧化铝、维生素B2、胃膜素、磷酸铝、甲氧基丙氧基、苯并咪唑钠盐，按上述重量配比混合打磨成粉，然后加入适量的水，加温至沸腾，最后冷却并过滤杂质即可。
本发明的有益效果为：疗效稳定、标本兼治，服用方便、简单，无异味且无毒性副作用，安全可靠，制造工艺简单，生产成本低，具有消炎、止痛功效，适合胃病患者使用。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合具体实施方式，对本发明进行进一步详细说明。应当理解，此处所描述的具体实施方式仅用以解释本发明，并不用于限定本发明。
实施例1：
一种用于结合治疗胃病的粘液西药，它由以下原料混合加工而成，各原料的重量配比如下：甲氧氯普胺片40mg、奥美拉唑30mg、氢氧化铝20mg、维生素B28mg、胃膜素15mg、磷酸铝10mg、甲氧基丙氧基5mg、苯并咪唑钠盐25mg。
所述的一种用于结合治疗胃病的粘液西药，其制备方法是：将上述重量配比的甲氧氯普胺片40mg、奥美拉唑30mg、氢氧化铝20mg、维生素B28mg、胃膜素15mg、磷酸铝10mg、甲氧基丙氧基5mg、苯并咪唑钠盐25mg，混合均匀并打磨成粉，然后加入适量的水，加温至沸腾，最后冷却并过滤杂质即可。
实施例2：
一种用于结合治疗胃病的粘液西药，它由以下原料混合加工而成，各原料的重量配比如下：甲氧氯普胺片60mg、奥美拉唑40mg、氢氧化铝45mg、维生素B215mg、胃膜素20mg、磷酸铝18mg、甲氧基丙氧基12mg、苯并咪唑钠盐35mg。
所述的一种用于结合治疗胃病的粘液西药，其制备方法是：将上述重量配比的甲氧氯普胺片60mg、奥美拉唑40mg、氢氧化铝45mg、维生素B215mg、胃膜素20mg、磷酸铝18mg、甲氧基丙氧基12mg、苯并咪唑钠盐35mg，混合均匀并打磨成粉，然后加入适量的水，加温至沸腾，最后冷却并过滤杂质即可。
实施例3：
一种用于结合治疗胃病的粘液西药，它由以下原料混合加工而成，各原料的重量配比如下：甲氧氯普胺片85mg、奥美拉唑50mg、氢氧化铝60mg、维生素B230mg、胃膜素40mg、磷酸铝25mg、甲氧基丙氧基15mg、苯并咪唑钠盐60mg。
所述的一种用于结合治疗胃病的粘液西药，其制备方法是：将上述重量配比的甲氧氯普胺片85mg、奥美拉唑50mg、氢氧化铝60mg、维生素B230mg、胃膜素40mg、磷酸铝25mg、甲氧基丙氧基15mg、苯并咪唑钠盐60mg，混合均匀并打磨成粉，然后加入适量的水，加温至沸腾，最后冷却并过滤杂质即可。
对于本领域技术人员而言，显然本发明不限于上述示范性实施例的细节，而且在不背离本发明的精神或基本特征的情况下，能够以其他的具体形式实现本发明。因此，无论从哪一点来看，均应将实施例看作是示范性的，而且是非限制性的，本发明的范围由所附权利要求而不是上述说明限定，因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。不应将权利要求中的任何附图标记视为限制所涉及的权利要求。
此外，应当理解，虽然本说明书按照实施方式加以描述，但并非每个实施方式仅包含一个独立的技术方案，说明书的这种叙述方式仅仅是为清楚起见，本领域技术人员应当将说明书作为一个整体，各实施例中的技术方案也可以经适当组合，形成本领域技术人员可以理解的其他实施方式。
Claims (5)
1.一种用于结合治疗胃病的粘液西药，其特征在于：它由以下原料混合加工而成，各原料的重量配比如下：甲氧氯普胺片40～85mg、奥美拉唑30～50mg、氢氧化铝20～60mg、维生素B2 8～30mg、胃膜素15～40mg、磷酸铝10～25mg、甲氧基丙氧基5～15mg、苯并咪唑钠盐25～60mg。
2.根据权利要求1所述的一种用于结合治疗胃病的粘液西药，其特征在于：所述一种用于结合治疗胃病的粘液西药，它由以下原料混合加工而成，各原料的重量配比如下：甲氧氯普胺片40mg、奥美拉唑30mg、氢氧化铝20mg、维生素B2 8mg、胃膜素15mg、磷酸铝10mg、甲氧基丙氧基5mg、苯并咪唑钠盐25mg。
3.根据权利要求1所述的一种用于结合治疗胃病的粘液西药，其特征在于：所述一种用于结合治疗胃病的粘液西药，它由以下原料混合加工而成，各原料的重量配比如下：甲氧氯普胺片85mg、奥美拉唑50mg、氢氧化铝60mg、维生素B230mg、胃膜素40mg、磷酸铝25mg、甲氧基丙氧基15mg、苯并咪唑钠盐60mg。
4.根据权利要求1所述的一种用于结合治疗胃病的粘液西药，其特征在于：所述一种用于结合治疗胃病的粘液西药，它由以下原料混合加工而成，各原料的重量配比如下：甲氧氯普胺片60mg、奥美拉唑40mg、氢氧化铝45mg、维生素B2 15mg、胃膜素20mg、磷酸铝18mg、甲氧基丙氧基12mg、苯并咪唑钠盐35mg。
5.根据权利要求1所述的一种用于结合治疗胃病的粘液西药，其特征在于：所述一种用于结合治疗胃病的粘液西药，其制备方法是：将甲氧氯普胺片、奥美拉唑、氢氧化铝、维生素B2、胃膜素、磷酸铝、甲氧基丙氧基、苯并咪唑钠盐，按上述重量配比混合打磨成粉，然后加入适量的水，加温至沸腾，最后冷却并过滤杂质即可。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710086313.7A CN106860852A (zh) | 2017-02-17 | 2017-02-17 | 一种用于结合治疗胃病的粘液西药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710086313.7A CN106860852A (zh) | 2017-02-17 | 2017-02-17 | 一种用于结合治疗胃病的粘液西药 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106860852A true CN106860852A (zh) | 2017-06-20 |
Family
ID=59166935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710086313.7A Pending CN106860852A (zh) | 2017-02-17 | 2017-02-17 | 一种用于结合治疗胃病的粘液西药 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106860852A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107998378A (zh) * | 2018-01-22 | 2018-05-08 | 马艳红 | 一种西药治疗胃病的胶囊 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004206141A1 (en) * | 2003-01-24 | 2004-08-05 | Niva Shapira | Synergistic compositions and methods for potentiating anti-oxidative activity |
| CN1911248A (zh) * | 2005-08-08 | 2007-02-14 | 巴文清 | 一种中西药结合治疗胃病的粘液药 |
| EP2208500A1 (en) * | 2009-01-16 | 2010-07-21 | Bionap S.r.L. | Compositions for the treatment of gerd (gastroesophageal reflux disease) |
| EP2564833A1 (en) * | 2008-07-28 | 2013-03-06 | Takeda Pharmaceutical Company Limited | Photostabilized pharmaceutical composition |
| CN105434459A (zh) * | 2015-12-25 | 2016-03-30 | 南阳医学高等专科学校 | 一种治疗溃疡的西药配方及其制备工艺 |
| CN105796712A (zh) * | 2016-06-03 | 2016-07-27 | 胡晨 | 一种用于治疗浅表性胃炎的中药组合物 |
-
2017
- 2017-02-17 CN CN201710086313.7A patent/CN106860852A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004206141A1 (en) * | 2003-01-24 | 2004-08-05 | Niva Shapira | Synergistic compositions and methods for potentiating anti-oxidative activity |
| CN1911248A (zh) * | 2005-08-08 | 2007-02-14 | 巴文清 | 一种中西药结合治疗胃病的粘液药 |
| EP2564833A1 (en) * | 2008-07-28 | 2013-03-06 | Takeda Pharmaceutical Company Limited | Photostabilized pharmaceutical composition |
| EP2208500A1 (en) * | 2009-01-16 | 2010-07-21 | Bionap S.r.L. | Compositions for the treatment of gerd (gastroesophageal reflux disease) |
| CN105434459A (zh) * | 2015-12-25 | 2016-03-30 | 南阳医学高等专科学校 | 一种治疗溃疡的西药配方及其制备工艺 |
| CN105796712A (zh) * | 2016-06-03 | 2016-07-27 | 胡晨 | 一种用于治疗浅表性胃炎的中药组合物 |
Non-Patent Citations (5)
| Title |
|---|
| ABBAS WASHEEL SALMAN: "Synthesis and Characterization of 1-benzylbenzimidazole complexes with some transition metal salts", 《AUSTRALIAN JOURNAL OF BASIC AND APPLIED SCIENCES》 * |
| SHANNON MATTHEW S. ET AL.: "Properties of alkylbenzimidazoles for CO2 and SO2 capture and comparisons to ionic liquids", 《SCIENCE CHINA CHEMISTRY》 * |
| 邹嵩: "胃病用药"四时五类"要对应", 《大众卫生报》 * |
| 阿龙: "一个西方药剂师眼中的中医药学-现状与对比", 《万方数据》 * |
| 陆恒: "《胃肠病病人最关心的288个问题》", 30 April 2015, 湖北科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107998378A (zh) * | 2018-01-22 | 2018-05-08 | 马艳红 | 一种西药治疗胃病的胶囊 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fathizadeh et al. | Evaluating the effect of magnesium and magnesium plus vitamin B6 supplement on the severity of premenstrual syndrome | |
| CN103798392B (zh) | 具有缓解咽喉部炎症功效的益生菌食品组合物及食品 | |
| US20220133782A1 (en) | Methods and compositions for using cinnamaldehyde and zinc for weight management | |
| US12161666B2 (en) | Composition comprising cinnamaldehyde and zinc to improve swallowing | |
| Nagaoka et al. | Effects of an indomethacin oral spray on pain due to oral mucositis in cancer patients treated with radiotherapy and chemotherapy: a double-blind, randomized, placebo-controlled trial (JORTC-PAL04) | |
| TWI329018B (en) | Anti-stress agent | |
| Ergül et al. | Efficacy and safety of gum chewing in adjunct to high-dose senna for bowel cleansing before colonoscopy: A single-blind randomized controlled trial | |
| CN106860852A (zh) | 一种用于结合治疗胃病的粘液西药 | |
| CN107624068B (zh) | 包含肉桂醛和锌的组合物及此类组合物的使用方法 | |
| CN106470691B (zh) | 包含肉桂醛和锌的组合物及此类组合物的使用方法 | |
| Casabianca et al. | Caffeine was associated with shorter continuous positive airway pressure treatment for infants up to eight weeks old hospitalised for bronchiolitis | |
| US9962387B2 (en) | Method of treating insomnia | |
| CN116077474A (zh) | 使用肉桂醛增加能量消耗的方法和组合物 | |
| US20130209581A1 (en) | Iodinated activated charcoal for treating symptoms of depression | |
| CN103082299B (zh) | 一种清肠排毒的营养保健品 | |
| Walter et al. | Hyponatraemia and brain oedema in newborns following oral water intoxication during prolonged labour | |
| Paturi et al. | Galactorrhea with metoclopramide use in the neonatal unit | |
| Shekarriz et al. | Pica: treatment with Punica Granatum extract | |
| CN108294138A (zh) | 一种既能提神醒脑又能缓解疲劳的饮料 | |
| Bedaso | Coffee consumption benefits and risks on human health | |
| Khan et al. | The effect of Shuneez (Nigella sativa) as galactogogue on mothers complaining of insufficient breast milk: A single-blind clinical trial | |
| Gaikwad et al. | Management of Vicharchika (Atopic Dermatitis): A Case Study | |
| CN101204537B (zh) | 一种疏风镇惊化痰导滞的中药组合物及其制备方法 | |
| Rajeshwari | Milk consumption and birth weight | |
| CN115397262A (zh) | 睡眠质量改善剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170620 |
|
| RJ01 | Rejection of invention patent application after publication |